ClinicalTrials.gov
Cure8 trial brief
Association Between LRG and Histologic Remission in Ulcerative Colitis
Tests and monitoring
Biomarkers
Biomarker
Phase 2 clinical trial
Ulcerative colitis
Inflammatory bowel disease
Why This Matters
Finding a blood biomarker that predicts histologic remission could make disease monitoring less invasive and help guide when colonoscopy is needed for people with ulcerative colitis.
Who Should Pay Attention
Adult patients with ulcerative colitis, gastroenterologists, and IBD researchers focused on biomarkers and noninvasive monitoring.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment100 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a registered observational study (recruiting) at Showa Inan General Hospital testing whether serum leucine-rich α2-glycoprotein (LRG) can predict histologic remission in ulcerative colitis (UC).
Participants will have serum LRG measured by ELISA; colonoscopy with histologic assessment (Geboes score) is performed when histologic remission is predicted, regardless of symptoms. The planned enrollment is 100 adults (age 20–90).
The study’s primary goal is to identify an LRG cutoff that predicts histologic remission (Geboes score <2) and to assess diagnostic performance using ROC analysis. This is an observational biomarker study, not a treatment trial; it measures LRG and compares it to endoscopy and histology findings.
If you have UC and are curious about noninvasive tests for mucosal healing, this trial is studying one candidate biomarker (LRG) that could help reduce unnecessary colonoscopies if validated.
Keep In Mind
Single-center observational study; planned enrollment 100; results would require external validation before clinical adoption.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorShowa Inan General Hospital
Trial IDNCT06372613
Study typeObservational
Enrollment100 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 11, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL）
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...